Molecular mechanism of point mutation-induced Monopolar spindle 1 (Mps1/TTK) inhibitor resistance revealed by a

Yan Han1, Yungang Wu1, Yi Xu2

  • 1Department of TCM Orthopedics & Traumatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Peerj
|January 30, 2019
PubMed
Abstract

Insights

Point mutations in Mps1 (Monopolar spindle 1) can cause resistance to cancer inhibitors. Molecular dynamics simulations revealed how these mutations alter Mps1 structure, affecting inhibitor binding and guiding the development of new drugs.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Research
  • Structural Biology

Background:

  • Monopolar spindle 1 (Mps1/TTK) is crucial for accurate chromosome segregation during mitosis.
  • Elevated Mps1 levels are linked to various human cancers, making it a therapeutic target.
  • Mps1 inhibitors show promise but face resistance due to kinase domain mutations.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying resistance to the Mps1 inhibitor Cpd-5 caused by specific point mutations.
  • To understand how these mutations affect Mps1 structure and inhibitor binding affinity.

Main Methods:

  • Conventional molecular dynamics (MD) simulations were employed.
  • Gaussian accelerated MD (GaMD) simulations were used to further investigate conformational changes.
  • Structural analysis and free energy calculations were performed on four representative Mps1 mutations (I531M, I598F, C604Y, S611R).

Main Results:

  • The four studied mutations significantly weaken the binding affinity of the Mps1 inhibitor Cpd-5.
  • Key structural alterations include conformational changes in the P-loop, A-loop, and αC-helix.
  • Mutations were found to allosterically regulate the conformational ensemble, particularly affecting residues Ile-663 and Gln-683.

Conclusions:

  • Detailed molecular mechanisms of Mps1 inhibitor resistance have been identified.
  • These findings provide a basis for the rational design of novel Mps1 inhibitors to overcome resistance.
  • Understanding resistance mechanisms is vital for developing effective cancer therapies targeting Mps1.